Open Access Repository

Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)


Downloads per month over past year

Ding, C and Jones, G 2006 , 'Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)' , Current Opinion in Investigational Drugs, vol. 7, no. 5 , pp. 464-472 .

[img] PDF
belimumab.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.


Belimumab, the lead in a series of human monoclonal antibodies against the human protein B-lymphocyte stimulator (BLyS), is under development by Human Genome Sciences, Cambridge Antibody Technology and GlaxoSmithKline for the potential treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). By January 2006, belimumab had completed phase II clinical trials in SLE and RA; a phase III clinical SLE trial is scheduled to begin later this year.

Item Type: Article
Authors/Creators:Ding, C and Jones, G
Journal or Publication Title: Current Opinion in Investigational Drugs
ISSN: 1472-4472
Additional Information:

restricted - published by Thompson

Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page